This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaminker, J. S. Articles by Zhang, Z. Search for Related Content PubMed PubMed Citation Articles by Kaminker, J. S. Articles by Zhang, Z.

Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms

Departments of ¹ Bioinformatics, ² Molecular Biology, ³ Biostatistics, and ⁴ Protein Engineering, Genentech, Inc., South San Francisco, California

Requests for reprints: Zemin Zhang, Bioinformatics, Genentech, Inc., South San Francisco, CA 94404. Phone: 650-225-4293; E-mail: zemin{at}gene.com.

Missense variants are commonly identified in genomic sequence but only a small fraction directly contribute to oncogenesis. The ability to distinguish those missense changes that contribute to cancer progression from those that do not is a difficult problem usually only accomplished through functional in vivo analyses. Using two computational algorithms, Sorting Intolerant from Tolerant (SIFT) and the Pfam-based LogR.E-value method, we have identified features that distinguish cancer-associated missense mutations from other classes of missense change. Our data reveal that cancer mutants behave similarly to Mendelian disease mutations, but are clearly distinct from either complex disease mutations or common single-nucleotide polymorphisms. We show that both activating and inactivating oncogenic mutations are predicted to be deleterious, although activating changes are likely to increase protein activity. Using the Gene Ontology and data from the SIFT and LogR.E-value metrics, a classifier was built that predicts cancer-associated missense mutations with a very low false-positive rate. The classifier does remarkably well in a number of different experiments designed to distinguish polymorphisms from true cancer-associated mutations. We also show that recurrently observed mutations are much more likely to be predicted to be cancer-associated than rare mutations, suggesting that our classifier will be useful in distinguishing causal from passenger mutations. In addition, from an expressed sequence tag–based screen, we identified a previously unknown germ line change (P1104A) in tumor tissues that is predicted to disrupt the function of the TYK2 protein. The data presented here show that this novel bioinformatics approach to classifying cancer-associated variants is robust and can be used for large-scale analyses. [Cancer Res 2007;67(2):465–73]

This article has been cited by other articles:

				B. Li, V. G. Krishnan, M. E. Mort, F. Xin, K. K. Kamati, D. N. Cooper, S. D. Mooney, and P. Radivojac Automated inference of molecular mechanisms of disease from amino acid substitutions Bioinformatics, November 1, 2009; 25(21): 2744 - 2750. [Abstract] [Full Text] [PDF]

				H. Carter, S. Chen, L. Isik, S. Tyekucheva, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, and R. Karchin Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations Cancer Res., August 15, 2009; 69(16): 6660 - 6667. [Abstract] [Full Text] [PDF]

				C. Liang, L. Liu, and G. Ji WebGMAP: a web service for mapping and aligning cDNA sequences to genomes Nucleic Acids Res., July 1, 2009; 37(suppl_2): W77 - W83. [Abstract] [Full Text] [PDF]

				O. Simma, E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau, E. Weisz, E. M. Putz, W. F. Pickl, et al. Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance Cancer Res., January 1, 2009; 69(1): 203 - 211. [Abstract] [Full Text] [PDF]

				C. J. Richardson, Q. Gao, C. Mitsopoulous, M. Zvelebil, L. H. Pearl, and F. M. G. Pearl MoKCa database--mutations of kinases in cancer Nucleic Acids Res., January 1, 2009; 37(suppl_1): D824 - D831. [Abstract] [Full Text] [PDF]

				S. J. Furney, B. Calvo, P. Larranaga, J. A. Lozano, and N. Lopez-Bigas Prioritization of candidate cancer genes--an aid to oncogenomic studies Nucleic Acids Res., October 1, 2008; 36(18): e115 - e115. [Abstract] [Full Text] [PDF]

				P. Radivojac, P. H. Baenziger, M. G. Kann, M. E. Mort, M. W. Hahn, and S. D. Mooney Gain and loss of phosphorylation sites in human cancer Bioinformatics, August 15, 2008; 24(16): i241 - i247. [Abstract] [Full Text] [PDF]

				M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia Blood, May 1, 2008; 111(9): 4797 - 4808. [Abstract] [Full Text] [PDF]

				A. Torkamani and N. J. Schork Prediction of Cancer Driver Mutations in Protein Kinases Cancer Res., March 15, 2008; 68(6): 1675 - 1682. [Abstract] [Full Text] [PDF]

				D. J. Sugarbaker, W. G. Richards, G. J. Gordon, L. Dong, A. De Rienzo, G. Maulik, J. N. Glickman, L. R. Chirieac, M.-L. Hartman, B. E. Taillon, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors PNAS, March 4, 2008; 105(9): 3521 - 3526. [Abstract] [Full Text] [PDF]

				R. S. Herbst, V. J. O'Neill, L. Fehrenbacher, C. P. Belani, P. D. Bonomi, L. Hart, O. Melnyk, D. Ramies, M. Lin, and A. Sandler Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer J. Clin. Oncol., October 20, 2007; 25(30): 4743 - 4750. [Abstract] [Full Text] [PDF]

				J. S. Kaminker, Y. Zhang, C. Watanabe, and Z. Zhang CanPredict: a computational tool for predicting cancer-associated missense mutations Nucleic Acids Res., July 13, 2007; 35(suppl_2): W595 - W598. [Abstract] [Full Text] [PDF]